BioCryst Pharmaceuticals (NASDAQ:BCRX) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.
Analyst Recommendations
This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Oyster Point Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
BioCryst Pharmaceuticals | 0 | 3 | 8 | 0 | 2.73 |
Oyster Point Pharma | 0 | 0 | 1 | 0 | 3.00 |
BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Oyster Point Pharma has a consensus target price of $50.00, suggesting a potential upside of 144.62%. Given Oyster Point Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than BioCryst Pharmaceuticals.
Risk & Volatility
BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.
Insider & Institutional Ownership
72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
BioCryst Pharmaceuticals | -233.45% | -328.70% | -71.11% |
Oyster Point Pharma | N/A | -39.61% | -37.68% |
Earnings & Valuation
This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
BioCryst Pharmaceuticals | $48.83 million | 39.70 | $-108,900,000.00 | ($0.94) | -11.62 |
Oyster Point Pharma | N/A | N/A | $-45,710,000.00 | ($9.97) | -2.05 |
Oyster Point Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Oyster Point Pharma beats BioCryst Pharmaceuticals on 8 of the 13 factors compared between the two stocks.